Last Updated: 4:00PM 21/09/2021

Investor Centre

Company Overview

Atomo Diagnostics Limited (ASX:AT1) is a world leader in the development of user friendly rapid diagnostic test products that simplify testing in decentralized settings. Headquartered in Sydney, Australia, the company specializes in creating integrated rapid diagnostic test (RDT) platforms and finished products for blood-based point-of-care testing (POCT).

The recipient of multiple international awards for innovation, Atomo’s unique all-in-one AtomoRapid™ handheld devices make it easy to test and screen for a range of infectious diseases and chronic conditions. Its patented products simplify testing procedures, reduce errors and enhance usability for professional users and untrained selftesters.

As well as commercializing rapid test products in its own brand, Atomo provides OEM solutions to specialist diagnostic and pharmaceutical companies worldwide. The company manufactures the first and only HIV self-test to have been approved to be used in Australia. 

Share Price Performance

Historical Share Price

Investor Contacts

Investor Relations

Atomo Diagnostics Limited
Level 12, 680 George Street,
Sydney NSW 2000

Ph: +61 477 858 444
investorqueries@atomodiagnostics.com

Share Registry

Link Market Services
Locked Bag A14,
Sydney South NSW 1235

Ph: 1300 554 474
registrars@linkmarketservices.com.au